Nevertheless, the emerging scenario continues to stimulate the scientific research towards therapeutic solutions that consider both Aβ and tau, as a therapeutic target for an effective fight against Alzheimer’s Disease. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.